Market Cap
US$7.8b
Last Updated
2019/12/07 23:31 UTC
Data Sources
Company Financials +
Executive Summary
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Amarin's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMRN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
5.5%
AMRN
-0.5%
US Biotechs
0.03%
US Market
1 Year Return
32.8%
AMRN
14.9%
US Biotechs
18.6%
US Market
Return vs Industry: AMRN exceeded the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: AMRN exceeded the US Market which returned 18.6% over the past year.
Shareholder returns
| AMRN | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.5% | -0.5% | 0.03% |
| 30 Day | 34.0% | 9.0% | 1.7% |
| 90 Day | 38.0% | 15.2% | 5.7% |
| 1 Year | 32.8%32.8% | 15.9%14.9% | 21.1%18.6% |
| 3 Year | 597.2%597.2% | 28.1%24.1% | 45.6%36.2% |
| 5 Year | 1978.7%1978.7% | 6.8%1.9% | 71.1%52.3% |
Price Volatility Vs. Market
How volatile is Amarin's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Can We See Significant Institutional Ownership On The Amarin Corporation plc (NASDAQ:AMRN) Share Register?4 weeks ago | Simply Wall St
Earnings Release: Here's Why Analysts Cut Their Amarin Corporation plc Price Target To US$29.111 month ago | Simply Wall St
When Will Amarin Corporation plc (NASDAQ:AMRN) Become Profitable?Valuation
Is Amarin undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMRN ($22.45) is trading below our estimate of fair value ($64.98)
Significantly Below Fair Value: AMRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMRN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: AMRN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMRN is overvalued based on its PB Ratio (14x) compared to the US Biotechs industry average (3.1x).
Next Steps
Future Growth
How is Amarin forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
75.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: AMRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMRN's is expected to become profitable in the next 3 years.
Revenue vs Market: AMRN's revenue (39% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: AMRN's revenue (39% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMRN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Amarin performed over the past 5 years?
1.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRN is currently unprofitable.
Growing Profit Margin: AMRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMRN is unprofitable, but has reduced losses over the past 5 years at a rate of 1.8% per year.
Accelerating Growth: Unable to compare AMRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: AMRN has a negative Return on Equity (-10.64%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Amarin's financial position?
Financial Position Analysis
Short Term Liabilities: AMRN's short term assets ($848.1M) exceed its short term liabilities ($229.7M).
Long Term Liabilities: AMRN's short term assets ($848.1M) exceed its long term liabilities ($41.3M).
Debt to Equity History and Analysis
Debt Level: AMRN's debt to equity ratio (10.1%) is considered satisfactory.
Reducing Debt: AMRN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Inventory Level: AMRN has a low level of unsold assets or inventory.
Debt Coverage by Assets: AMRN's debt is covered by short term assets (assets are 14.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMRN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AMRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Amarin's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate AMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Amarin's salary, the management and board of directors tenure and is there insider trading?
3.9yrs
Average management tenure
CEO
John Thero (58yo)
5.9yrs
Tenure
US$4,205,779
Compensation
Mr. John F. Thero has been the Chief Executive Officer of Amarin Corporation Plc since January 1, 2014 and has been its President since November 2010. Mr. Thero serves as the President of U.S. at Amarin Co ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD4.21M) is below average for companies of similar size in the US market ($USD6.81M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
3.9yrs
Average Tenure
52.5yo
Average Age
Experienced Management: AMRN's management team is considered experienced (3.9 years average tenure).
Board Age and Tenure
9.9yrs
Average Tenure
69yo
Average Age
Experienced Board: AMRN's board of directors are considered experienced (9.9 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.7%.
Management Team
John Thero (58yo)
President
- Tenure: 5.9yrs
- Compensation: US$4.21m
Steve Ketchum (54yo)
President of Research & Development
- Tenure: 3.9yrs
- Compensation: US$1.33m
Keith Wood
Head of Research and Development Operations
- Tenure: 12yrs
Joe Kennedy (51yo)
Executive VP
- Tenure: 8yrs
- Compensation: US$1.36m
Dan Dunham
Senior VP & Chief Pharmaceutical Compliance Officer
- Tenure: 1.2yrs
Mike Kalb (48yo)
CFO, Senior VP & Assistant Secretary
- Tenure: 3.5yrs
- Compensation: US$1.27m
Gwen Fisher
Vice President of Corporate Communications
- Tenure: 0.6yrs
Rami Daoud
Senior Vice President of Corporate Development
- Tenure: 3.9yrs
Donna Pasek
Vice President of Human Resources
- Tenure: 6.3yrs
Elisabeth Schwartz
Senior Director of Investor Relations
- Tenure: 0yrs
Board Members
John Thero (58yo)
President
- Tenure: 5.9yrs
- Compensation: US$4.21m
John Climax (66yo)
Chairman of Scientific Advisory Board
- Tenure: 13.6yrs
- Compensation: US$39.00k
G. van Heek (69yo)
Independent Non-Executive Director
- Tenure: 9.8yrs
- Compensation: US$282.50k
Dave Stack (69yo)
Non-Executive Independent Director
- Tenure: 7yrs
- Compensation: US$270.00k
Lars Ekman (69yo)
Chairman & Lead Independent Director
- Tenure: 5.9yrs
- Compensation: US$320.01k
Jan Wallace (78yo)
Member of Scientific Advisory Board
- Tenure: 13.6yrs
Joe Zakrzewski (57yo)
Non-Executive Director
- Tenure: 9.9yrs
- Compensation: US$260.00k
Mark Pierce
Member of the Scientific Advisory Board
- Tenure: 13.6yrs
Reid Patterson
Member of the Scientific Advisory Board
- Tenure: 13.6yrs
Paddy O'Sullivan (77yo)
Non-Executive Director
- Tenure: 8yrs
- Compensation: US$275.00k
Company Information
Amarin Corporation plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Amarin Corporation plc
- Ticker: AMRN
- Exchange: NasdaqGM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.763b
- Shares outstanding: 358.91m
- Website: https://www.amarincorp.com
Number of Employees
Location
- Amarin Corporation plc
- Grand Canal Docklands
- Block C
- Dublin
- Co. Dublin
- 2
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AMRN | NasdaqGM (Nasdaq Global Market) | Yes | ADR EACH REP 1 ORD GBP0.50 | US | USD | Apr 1993 |
| EH3A | DB (Deutsche Boerse AG) | Yes | ADR EACH REP 1 ORD GBP0.50 | DE | EUR | Apr 1993 |
Biography
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead prod ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/07 23:31 |
| End of Day Share Price | 2019/12/06 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.